Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

no longer respond to the standard of care under Fast Track designation from the U.S. Food and Drug Administration.

About Carcinoid Syndrome

Carcinoid syndrome is a chronic condition caused by metastatic neuroendocrine tumors that usually originate from the gastrointestinal tract. These tumors secrete large amounts of serotonin, which can cause a variety of symptoms including severe diarrhea and abdominal discomfort. Patients with carcinoid syndrome currently have limited therapeutic options, and the standard of care includes chronic therapy with somatostatin analogues, which are delivered by injection. With current therapy, the gastrointestinal symptoms return over time in the vast majority of patients, hence the need for new agents.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX1032 and the potential therapeutic and commercial potential of LX1032. This press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... release its non-invasive hydration monitoring wearable early 2016. , The device, called ... using proprietary optical and electrical sensing technology. These sensors track trending interstitial ...
(Date:9/2/2015)... (PRWEB) , ... September 02, ... ... provider of regulatory compliance, quality systems, analytical testing, education and consulting services ... with expertise in medical device products/processes development, design control, validation, quality assurance ...
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... botanical and plant-derived compounds. BCC Research reveals in its new report that ... this market defines the category and generates the most market demand. , ...
Breaking Biology Technology:Technology Startup Halo Wearables to Unveil Non-Invasive Hydration Monitoring Device Early 2016 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... MedImmune announced today it,will present four abstracts ... Conference & Exhibition that add to the company,s ... syncytial virus (RSV),a leading cause of viral respiratory ... data that further demonstrate the burden of RSV ...
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced it ... provide an update on the,Viprinex(TM) (ancrod) Phase 3 Trial ... Paul E. Freiman, president and chief executive,officer and Warren ... Monday, October 13, 2008 -- Time: 1:00 ...
... 10 CSMG,Technologies, Inc., (OTC Bulletin Board: ... has received approval of its fifth U.S.,patent. ... application for "Bonding of,Soft Biological Tissues by ... Technologies subsidiary Live Tissue Connects ("LTC"),platform tissue ...
Cached Biology Technology:MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 2MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 3MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 4MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease 5Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 2CSMG Technologies Announces Key Fifth U.S. Tissue Bonding/Welding Patent Approved 3
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... and editors of the Pensoft journal ZooKeys carried ... (84 %) are willing to publish their data, so that ... integrate with other data" said Dr Lyubomir Penev, managing director ... data, the scientists mentioned that "open data increases ...
... Jerusalem 31 May 2011 - Parliamentarians ... the Knesset (parliament) today for the 17th EUREKA ... a growth in market-oriented R&D projects and to ... by Knesset Science and Technology Committee head Meir ...
... research raises the possibility that the critically short supply ... treating so-called "marginal" livers with a substance that protects ... supplies. The report appears in ACS, journal Molecular ... the need for liver transplants has grown over the ...
Cached Biology News:Data publishing policies and guidelines for biodiversity data by Pensoft 2
High-throughput DNA sequencing of any library. Just give us your transformation mixture, and we'll do the rest. ABI 3730xl's yield the longest read lengths available. LIMS tracking utilizing Geospiza...
... pass sequencing of plasmids and PCR ... our high performance sequencing pipeline which ... per day. The key benefits we ... are rapid turnaround, high sequencing pass ...
... high quality whole genome sequencing service. Our ... allow even the smallest of laboratories to ... features which set our whole genome sequencing ... strategies, proprietary assembly software, rapid project turnaround ...
Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
Biology Products: